Infused chemotherapy use in the elderly after patent expiration Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Camptothecin
  • Neoplasms
  • Organoplatinum Compounds
  • Patents as Topic
  • Practice Patterns, Physicians'

abstract

  • This study provides novel and robust estimates of the decline in use of a chemotherapy to treat a common cancer in the elderly after patent expiration. The results suggest estimates from a previous Office of the Inspector General report of the potential savings derived from the generic entry of irinotecan for public payers are an overestimate, likely confounded by oncologists' response to financial incentives, changes in scientific evidence, and promotional activities. As calls for improving the quality and cost efficiency of oncology increase, future empirical work is needed to examine the responsiveness of oncologists' treatment decision making to incentives among patients of all ages and insurance types.

publication date

  • May 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 22694111

Additional Document Info

start page

  • e173

end page

  • 8

volume

  • 18

number

  • 5